Ladenstein R, Gadner H, Hartmann O, Pico J, Biron P, Thierry P
Centre Léon Bérard, Lyon.
Wien Med Wochenschr. 1995;145(2-3):55-7.
Since 1984 a total of 2085 patients with solid tumors have been registered in the European Bone Marrow Transplantation Registry for Solid Tumors (EBMT-STR). The major aim of this registry is to supply data by retrospective analysis for the innovation of prospective, randomized studies. 104 Ewing's sarcoma patients received megatherapy followed by autologous bone marrow transplantation (MGT/ABMT). The 2-year overall survival was 31% in 14 patients with multifocal disease in first complete remission (CR1) and was 37% for 15 patients in second CR (CR2). (6 patients with local disease in CR1 have been excluded.) These results are better than observed under conventional dose chemotherapy. 67 patients were grafted with measurable disease showing a response rate of 72%. The 2-year overall survival was 25% during primary treatments and 33% and 10% for sensitive and resistant relapses, respectively. 201 patients with germ cell tumors received MGT (combinations of platinum derivates, VP16, cyclophosphamide, ifosfamide) followed by ABMT. The overall survival at 5 years was 10% in refractory patients and 58% for 113 responding patients not in CR1 (i.e. first partial remission, CR2 and sensitive relapses). Based on these results and a French randomized trial a prospective, randomized study is underway comparing MGT versus conventional chemotherapy in chemosensitive patients. 219 adults with malignant brain gliomas underwent a program consisting of surgery, MGT (BCNU in the majority)/ABMT and radiotherapy. The overall survival at 3 years was 12%, the median survival was 11 months after ABMT. Life quality after ABMT was good, but no major improvement in terms of prolonged survival was achieved.(ABSTRACT TRUNCATED AT 250 WORDS)
自1984年以来，共有2085例实体瘤患者被登记在欧洲实体瘤骨髓移植登记处（EBMT-STR）。该登记处的主要目的是通过回顾性分析提供数据，以推动前瞻性随机研究的创新。104例尤因肉瘤患者接受了大剂量治疗，随后进行自体骨髓移植（MGT/ABMT）。14例首次完全缓解（CR1）的多灶性疾病患者的2年总生存率为31%，15例第二次完全缓解（CR2）的患者为37%。（6例CR1期局部疾病患者被排除。）这些结果优于传统剂量化疗。67例有可测量疾病的患者接受了移植，缓解率为72%。初次治疗期间的2年总生存率为25%，敏感复发和耐药复发的患者分别为33%和10%。201例生殖细胞肿瘤患者接受了MGT（铂衍生物、VP16、环磷酰胺、异环磷酰胺联合使用），随后进行ABMT。难治性患者的5年总生存率为10%，113例未处于CR1期（即首次部分缓解、CR2和敏感复发）的缓解患者为58%。基于这些结果和一项法国随机试验，一项比较MGT与传统化疗对化疗敏感患者疗效的前瞻性随机研究正在进行。219例成年恶性脑胶质瘤患者接受了包括手术、MGT（多数使用卡莫司汀）/ABMT和放疗的治疗方案。3年总生存率为12%，ABMT后的中位生存期为11个月。ABMT后的生活质量良好，但在延长生存期方面未取得重大改善。（摘要截取自250词）
